{"id":"tp-53084","type":"article-newspaper","title":"ImmunityBio Revenue Climbs 53% as Quarterly Loss Widens","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/53084","datePublished":"2026-11-10T12:40:58.000Z","dateModified":"2026-11-10T12:40:58.000Z","language":"en","abstract":"Nine-month net product revenue rose 92% to $143.6 million. ImmunityBio plans to submit a supplemental biologics license application for BCG-naive patients before year-end.","section":"Business","references":[]}